Gene-Mediated Immunotherapy for Ovarian Cancer Clears Safety Hurdle, Will Continue Dosing

The phase 1/2 OVATION 2 study is expected to complete enrollment by the third quarter of this year.

Thomas Martin, MD, on Exciting Cell Therapy Options in Multiple Myeloma

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.

Around the Helix: Cell and Gene Therapy Company Updates – June 22, 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.